A Phase IIa Study to Build an Understanding of the Pharmacokinetic-Pharmacodynamic Relationship of PSN821 in Type 2 Diabetes Patients (T2DM).

Trial Profile

A Phase IIa Study to Build an Understanding of the Pharmacokinetic-Pharmacodynamic Relationship of PSN821 in Type 2 Diabetes Patients (T2DM).

Completed
Phase of Trial: Phase I/II

Latest Information Update: 16 Aug 2012

At a glance

  • Drugs PSN 821 (Primary)
  • Indications Obesity; Type 2 diabetes mellitus
  • Focus Pharmacodynamics
  • Most Recent Events

    • 16 Aug 2012 Actual end date (May 2012) added as reported by ClinicalTrials.gov.
    • 11 Oct 2011 Planned end date changed from 1 Dec 2011 to 1 Jun 2012 as reported by ClinicalTrials.gov.
    • 11 Oct 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top